anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Despite considerable investigative efforts, the molecular mechanisms of postoperative delirium (POD) remain unresolved. The present investigation employs innovative methodologies for identifying potential primary and secondary metabolic markers of POD by analyzing serum metabolomic profiles utilizing the genetic algorithm and artificial neural networks. The primary metabolomic markers constitute a combination of metabolites that optimally distinguish between POD and non-POD groups of patients. Our analysis revealed L-lactic acid, inositol, and methylcysteine as the most salient primary markers upon which the prediction accuracy of POD manifestation achieved AUC = 99%. The secondary metabolomic markers represent metabolites that exhibit perturbed correlational patterns within the POD group. We identified 54 metabolites as the secondary markers of POD, incorporating neurotransmitters such as gamma-aminobutyric acid (GABA) and serotonin. These findings imply a systemic disruption in metabolic processes in patients with POD. The deployment of gene network reconstruction techniques facilitated the postulation of hypotheses describing the role of established genomic POD markers in the molecular-genetic mechanisms of metabolic pathways dysregulation, and involving the identified primary and secondary metabolomic markers. This study not only expands the understanding of POD pathogenesis but also introduces a novel technology for the bioinformatic analysis of metabolomic data that could aid in uncovering potential primary and secondary markers in diverse research domains.
Raloxifene hydrochloride tablets are contraindicated in pregnancy, in women who may become pregnant, and in nursing mothers [see Use in Specific Populations (8.1, 8.3)]. Raloxifene hydrochloride tablets may cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

In rabbit studies, abortion and a low rate of fetal heart anomalies (ventricular septal defects) occurred in rabbits at doses ≥0.1 mg/kg (≥0.04 times the human dose based on surface area, mg/m2), and hydrocephaly was observed in fetuses at doses ≥10 mg/kg (≥4 times the human dose based on surface area, mg/m2). In rat studies, retardation of fetal development and developmental abnormalities (wavy ribs, kidney cavitation) occurred at doses ≥1 mg/kg (≥0.2 times the human dose based on surface area, mg/m2). Treatment of rats at doses of 0.1 to 10 mg/kg (0.02 to 1.6 times the human dose based on surface area, mg/m2) during gestation and lactation produced effects that included delayed and disrupted parturition; decreased neonatal survival and altered physical development; sex- and age-specific reductions in growth and changes in pituitary hormone content; and decreased lymphoid compartment size in offspring. At 10 mg/kg, raloxifene disrupted parturition, which resulted in maternal and progeny death and morbidity. Effects in adult offspring (4 months of age) included uterine hypoplasia and reduced fertility; however, no ovarian or vaginal pathology was observed.
Liposomes are recovered from a soln. of lipids by drawing the soln. (32) from a vessel (20) with or without the addn. of activating agents and passing it through a coarse filter (11), a finer filter (12) and further filters (13,14) of increasing fineness until the required liposome size has been reached. The appts. used consists of a pump unit (30) and a filter unit (10) with a collecting vessel (20). The filter unit (10) has at least two parallel sections (11-14) of different filter fineness which are selected by a distributor valve (23) and whose outlets are all connected to the common collecting vessel (20). This collecting vessel (20) is connected to the pump unit (30) by a valve (28) and a pipe (31) so that the soln. (32) can be recirculated. USE/ADVANTAGE - Currently used systems for the recovery of liposomes use pressurised air or nitrogen to force the lipid solution through a fine filter of a fixed filter pore size. This process leads to results which are not repeatable and to the prodn. of vesicles of differing sizes which are unsuitable for use as active agent carriers in medical applications. This invention overcomes these difficulties and produces liposomes of uniform and unvarying size.
The invention discloses a citric acid pentovirine oral cavity film and a preparation method thereof. The citric acid pentovirine oral cavity film comprises the following components: the composition comprises the components of the pentofacillin citrate, a film-forming material, a plasticizer, a disintegrating agent, a pH regulator, a flavoring agent and a coloring agent. The components of the pentovirine citrate are as follows by weight percent: 20-50% of citric acid pentovirine, 30-70% of film forming material and 5-60% of additive. Wherein the film forming material is polyvinyl alcohol or a combination of polyvinyl alcohol and sodium alginate, more preferably a combination of polyvinyl alcohol and sodium alginate. The citric acid spray tolverine oral film prepared by the invention can be cut into the required size according to actual requirements, and the condition of uneven tablet distribution can not occur; the medicine can be dissolved rapidly in the oral cavity and swallowed along with saliva, so that the medicine absorption and the curative effect are accelerated. The preparation process of the citric acid pentovirine oral film is simple in process, easy to control and suitable for industrial production.
The invention relates to a formulation aiming at the treatment of bedsores and atonic ulcers of cell tissue, which formulation contains an extract of the following mother tinctures: 1. Alkanna tinctoria, suppressor of topoisomerase. 2. Capsela bursa pastoris with a mechanism of action acting as an antagonist of the growth factor receptors and signal transduction, inhibiting the tyrosine kinase pathway. 3. Stachys sylvatica. 4. Solidago virgaurea exhibiting similar and complementary action as antioxidants and anti-inflammatories but, mainly, as anti-nephrotics and styptics and, specifically, as non-electrolytic osmotic diuretics for better detoxification. 5.Chamomilla matricaria acting as an antimicrobial but also as analgesic.
Mechanism of Action: Posaconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14α-demethylase responsible for the conversion of lanosterol to ergosterol in the fungal cell membrane. This results in an accumulation of methylated sterol precursors and a depletion of ergosterol within the cell membrane thus weakening the structure and function of the fungal cell membrane. This may be responsible for the antifungal activity of posaconazole. 

Resistance: Clinical isolates of Candida albicans and Candida glabrata with decreased susceptibility to posaconazole were observed in oral swish samples taken during prophylaxis with posaconazole and fluconazole, suggesting a potential for development of resistance. These isolates also showed reduced susceptibility to other azoles, suggesting cross-resistance between azoles. The clinical significance of this finding is not known. 

Antimicrobial Activity: Posaconazole has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections [see Indications and Usage (1)]. 

Microorganisms:Aspergillus spp. and Candida spp.

Susceptibility Testing: For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
AKI is characterized by a sudden, and usually reversible, decline in kidney function. In mice, ischemia-reperfusion injury (IRI) is commonly used to model the pathophysiologic features of clinical AKI. Macrophages are a unifying feature of IRI as they regulate both the initial injury response as well as the long-term outcome following resolution of injury. Initially, macrophages in the kidney take on a proinflammatory phenotype characterized by the production of inflammatory cytokines, such as CCL2 (monocyte chemoattractant protein 1), IL-6, IL-1 β , and TNF- α . Release of these proinflammatory cytokines leads to tissue damage. After resolution of the initial injury, macrophages take on a reparative role, aiding in tissue repair and restoration of kidney function. By contrast, failure to resolve the initial injury results in prolonged inflammatory macrophage accumulation and increased kidney damage, fibrosis, and the eventual development of CKD. Despite the extensive amount of literature that has ascribed these functions to M1/M2 macrophages, a recent paradigm shift in the macrophage field now defines macrophages on the basis of their ontological origin, namely monocyte-derived and tissue-resident macrophages. In this review, we focus on macrophage phenotype and function during IRI-induced injury, repair, and transition to CKD using both the classic (M1/M2) and novel (ontological origin) definition of kidney macrophages.
Cirrhosis impairs macrophage function and disrupts bile acid homeostasis. Although bile acids affect macrophage function in patients with sepsis, whether and how the bile acid profile is changed by infection in patients with cirrhosis to modulate macrophage function remains unclear. The present study aimed to investigate the changes in the bile acid profile of patients with cirrhosis and infection and their effects on macrophage function. Serum was collected from 20 healthy subjects, 18 patients with cirrhosis and 39 patients with cirrhosis and infection. Bile acid profiles were detected using high‑performance liquid chromatography‑triple time‑of‑flight mass spectrometer. The association between bile acid changes and infection was analysed using receiver operating characteristic (ROC) curves. Infection‑altered bile acids were used in combination with lipopolysaccharides (LPS) to stimulate RAW264.7/THP‑1 cells in vitro. The migratory capacity was evaluated using wound healing and Transwell migration assays. The expression of Arg‑1, iNOS, IκBα, phosphorylated (p‑)IκBα and p65 was examined with western blotting and immunofluorescence, Tnfα, Il1b and Il6 mRNA was examined with RT‑qPCR, and CD86, CD163 and phagocytosis was measured with flow cytometry. The ROC curves showed that decreased hyodeoxycholic acid (HDCA) and deoxycholic acid (DCA) levels were associated with infection. HDCA or DCA combined with LPS enhanced the phagocytic and migratory ability of macrophages, accompanied by upregulation of iNOS and CD86 protein expression as well as Tnfα, Il1b, and Il6 mRNA expression. However, neither HDCA nor DCA alone showed an effect on these phenotypes. In addition, DCA and HDCA acted synergistically with LPS to increase the expression of p‑IκBα and the intranuclear migration of p65. Infection changed the bile acid profile in patients with cirrhosis, among which the reduction of DCA and HDCA associated most strongly with infection. HDCA and DCA enhanced the sensitivity of macrophage function loss to LPS stimulation. These findings suggested a potential role for monitoring the bile acid profile that could help manage patients with cirrhosis and infection.
Patients in the REx program are submitted to resistance machine exercises for the major muscle groups aiming to achieve the intensity of 80% of 1-Repetition Maximum (1-RM). A warmup and cool down of 10 and 5 minutes, respectively, were included in each session aiming workloads of 60%-85% of peak heart rate (HRp). Enrolment through the REx program resistance machines will be conducted from major muscle groups to minor muscle groups, from polyarticular to monoarticular exercises, and alternating between agonist and antagonist contraction according to the following laydown: Leg Press -\> Leg Curl -\> Leg Extension -\> Chest Press -\> Latissimus Pulldown -\> Shoulder Press -\> Triceps Extension -\> Biceps Curl -\> Abdominal Crunch.
The control condition will account for the time spent with rehabilitation therapists and study staff and provide more general cognitive stimulation. The control group will receive usual, standard of care occupational therapy during OT by inpatient rehabilitation staff who are not trained in the Multicontext approach. The standard OT session often focuses on cognition in a non-standardized and non-targeted manner without the targeting of WM and guided self-discovery of the Multicontext approach. To control for the cognitive training element of ASCEND, individuals randomized to the control condition will meet with a study staff member for 30 minutes of general cognitive stimulation that includes word-searches, crossword puzzles, and/or jigsaw puzzles.
Follows the 2013 World Health Organization (WHO) HIV treatment guidelines. Study participants will receive adherence support and return for a repeat viral load test in 3 months (or in 1 month for pregnant participants). Treatment failure will be defined by two consecutive viral load measurements greater than 1,000 copies/mL. Participants who meet this criteria will be switched to second-line therapy. Those with a viral load \<1,000 copies/mL at repeat testing will be retained on first-line therapy.
The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri DSM 17938 is 1x108 live bacteria (CFU)/tablet.
Patients in intensive care units with acute kidney injury are often too frail to undergo the rapid fluid shifts that accompany intermittent hemodialysis. Continuous renal replacement therapy (CRRT) allows a more gentle continual dialysis, more similar to regular kidney function. Anticoagulation of the CRRT circuit can reduce clotting of the filter, which can lead to less filter changes and possibly less transfusions. Niyad (nafamostat mesylate), an anticoagulant with an ultra-short half-life of 8 minutes, is approved for use in South Korea and Japan for anticoagulation of the CRRT circuit. For patients who cannot tolerate heparin or who are at a high risk of bleeding, nafamostat may be an optimal anticoagulant to infuse into the CRRT circuit as the short half-life should minimize patient exposure. The primary objective of this study is to measure the anticoagulation efficacy of Niyad in the CRRT circuit versus placebo. Evaluation of the safety of Niyad in patients undergoing CRRT versus placebo will also be performed.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor excellent in inhibiting effects on the lipid peroxide production and having high safety by including an extract of Guazuma ulmifolia (Cuaulote). SOLUTION: This inhibitor is obtained by including an extract of Guazuma ulmifolia (Cuaulote). The amount of an extracting solvent (e.g. water or ethanol) used for the extract of the Guazuma ulmifolia (Cuaulote) is 100 pts. for 5-50 pts. based on and expressed in terms of a dried substance of the dried plant or the live plant. A method for extraction is carried out at normal temperature or under heating, and usual extraction and extraction, or the like, with a Soxhlet extractor are cited. The extraction time is preferably 1 hr to 1 week. The amount of the extract of the Guazuma ulmifolia (Cuaulote) used as the inhibitor based on and expressed in terms of a dried substance is preferably 0.01-10 wt.% based on the total amount. A composition containing the inhibitor is used for cosmetics, foods, medicines, or the like.  The dosage form includes a toilet lotion, a milky lotion, or the like, in the case of the cosmetics and a tablet, a granule, a capsule, or the like, in the case of the medicines.
<P>PROBLEM TO BE SOLVED: To make a medical information processor on which a program capable of processing a plurality of types of medical information is loaded selectively process a type of medical information according to the use of the pertinent device.  <P>SOLUTION: A medical information processor 1 stores a presentation program 31 and authentication information 32. The authentication information 32 includes device ID and consent type information showing the consent type of presentation by the device. An information type specification part 61 specifies the type of medical information recorded in a recording medium 200. A device ID acquisition part 62 acquires the device ID from a network board 5. A license determination part 63 determines the presence/absence of the consent of the presentation of the pertinent type of medical information by the medical information processor 1 on the basis of specific classification, acquired device ID and the authentication information 32. Only when the presence of the consent of presentation is determined, the control part 2 makes a display part 71 display medical information recorded in the medical media 200.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A stable and porous lyophilized cake or powder is disclosed, which contains paclitaxel or another water-insoluble taxoid drug. This preparation is created by dissolving a taxoid drug in oil and a surfactant, with each component selected to provide a final product that will be benign and gentle, compared to the harsher and more toxic carriers used in paclitaxel emulsions today. An alcohol can also be used during the drug mixing step, but it should be removed before subsequent processing. The oily solution is mixed with an aqueous solution containing an non-proteinous anti-adhesion agent with a collapse temperature preferably in a range of about −25° C. to about −35° C., such as sucrose. The mixture is processed to form an emulsion, with oil droplets averaging less than about 2 microns (and preferably less than 1 micron) in diameter. This emulsion is passed through a sterilization filter and loaded into vials, and is lyophilized to form a porous cake or powder which is stable and can be stored for long periods without refrigeration. The cake or powder can be reconstituted with water shortly before use, to form an injectable emulsion or suspension which does not contain harsh and potentially toxic solubilizing agents or surfactants, and which contains oil droplets with very small diameters.
The invention provides a capsule containing a nicotinic acid slow-release tablet and a simvastatin mixture. The compound slow-release capsule preparation includes the nicotinic acid slow-release tablet and the simvastatin mixture, wherein the content of the nicotinic acid is 50%-80%. The simvastatin mixture includes the simvastatin and other medical auxiliary materials, wherein the content of the simvastatin is 20%-80%. The invention provides the preparation method of the compound slow-release capsule preparation of nicotinic acid and simvastatin. The preparation method comprises the following steps of: preparing the simvastatin and the medical auxiliary materials into a simvastatin mixture; preparing the nicotinic acid and the medical auxiliary materials into a slow-release tablet; filling the simvastatin mixture to the capsule by using a capsule filling machine; filling the nicotinic acid slow-release tablet to the capsule to obtain the nicotinic acid-simvastatin slow release capsule. The compound slow-release capsule preparation disclosed by the invention is good in stability, controllable in quality, simple in preparation method, suitable for industrial production and large in application value.
The premature baby's Oragastric tube will be fixed using a hydrocollaid dressing. Orogastric fixation will not be changed for 24 days. After 24 hours, the fixed patch will be removed using a silicone-based spray remover.
Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take ziprasidone oral capsule twice daily added to their regular open-label ziprasidone dose (total of 240 mg/d). After the first week, the study drug will be increased to a total ziprasidone dose of 320 mg/d for 7 weeks.
OBJECTIVES: To determine the association between elevated (> 1.5 multiples of the median (MoM)) middle cerebral artery (MCA) peak systolic velocity (PSV) and fetal demise of the donor twin in pregnancies complicated by twin-twin transfusion syndrome (TTTS) in the absence of twin anemia-polycythemia sequence (TAPS). Secondary objectives were to evaluate if donor or recipient MCA-PSV is associated with a risk for their corresponding fetal death, and to compare the proportion of donor fetuses with low MCA pulsatility index (PI) among donor twins with high MCA-PSV and those with normal MCA-PSV to evaluate the contribution of blood-flow redistribution to the fetal brain in donor twins with high MCA-PSV.
METHODS: This prospective cohort study included TTTS cases that underwent laser surgery between 2011 and 2022 at a single center. TAPS cases were excluded from the study. Multivariable and Poisson regression analysis were performed to explore the association between isolated elevated donor MCA-PSV and fetal demise, adjusted for TTTS stage, selective fetal growth restriction (sFGR) and other confounders.
RESULTS: Of 660 TTTS cases, donor MCA-PSV was not recorded in 48 (7.3%) cases. Of the remaining 612 patients, nine (1.5%) were lost to follow-up and 96 TAPS cases were excluded; thus, 507 cases were included in the study. High donor MCA-PSV was seen in 6.5% (33/507) of cases and was an independent risk factor for donor fetal demise (adjusted relative risk (aRR), 4.52 (95% CI, 2.72-7.50)), after adjusting for confounders. Regression analysis restricted to each Quintero TTTS stage demonstrated that high donor MCA-PSV was an independent risk factor for fetal demise of the donor in Quintero Stage II (aRR, 14.21 (95% CI, 1.09-186.2)) and Quintero Stage III (aRR, 3.41 (95% CI, 1.82-6.41)). Donor MCA-PSV in MoM was associated with fetal demise of the donor (area under the receiver-operating-characteristics curve (AUC), 0.69; P < 0.001), but recipient MCA-PSV in MoM was not associated with fetal demise of the recipient (AUC, 0.54; P = 0.44). A higher proportion of donor twins in the group with high MCA-PSV had a low MCA-PI compared to the group with normal MCA-PSV (33.3% vs 15.5%; P = 0.016).
CONCLUSIONS: Elevated donor MCA-PSV without TAPS prior to laser surgery for TTTS is associated with a 4-fold increased risk for donor fetal demise, adjusted for sFGR, TTTS stage and other confounders. Doppler evaluation of donor MCA-PSV prior to laser surgery may help stratify TTTS staging to evaluate the risk of donor fetal demise. © 2024 International Society of Ultrasound in Obstetrics and Gynecology.
PURPOSE:To analyze easily the plural antigens or antibodies in an unknown sample with high accuracy by applying further microcapsules of liposome, etc. by each mol.wt. to the coarsely fractionated sample. CONSTITUTION:A sample liquid 1 is passed by a metering pump 4 to a column 5 and the successively eluted peak fractions are gathered to a microplate 8 for analyzing the sample by each peak while the elution curve at the absorbancy of a prescribed wavelength is obtd. by a continuous absorbancy recorder 6. The coarsely fractionated primary samples 9 are thus obtd. The primary sample 9 and a microcapsule 10 formed by depositing either of a hydrophilic antigen or antibody conjugating specifically with the component to be analyzed of the primary sample 9 on the surface and sealing carboxy fluoresceine therein as a hydrophilic labeling material are then brought into contact and reaction with each other on the plate 8. The labeling material discharged by such reaction is detected and measured by a fluorescence spectrophotometer 11, by which the quantitative and qualitative analysis of the component to be analyzed is executed.